NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
In light of the increased use of CRA by federal agencies, the Department of Health and Human Services (DHHS) and the Food and Drug Administration (FDA) asked the National Research Council to convene an expert committee to develop and apply an evidence-based conceptual model and methods for ranking categories of products addressed by FDA programs. The conceptual model and methods were to focus on ranking product categories according to the ranges of magnitude of various potential health consequences to U.S. users of the products at the individual level and the population level, taking both adverse and beneficial effects into consideration. To accomplish its task, the committee was to include the following activities: consult with the sponsor to select FDA product categories to be ranked; consider products currently in use and near-term future products expected to come under FDA purview; review selected scientific literature bearing on adverse and beneficial health consequences; consider the scientific literature broadly to include social-science and economics literature, gray literature, and regulatory-policy literature; seek opportunities to assess health consequences in a way that allows results to be compared among broad product categories; identify information needed to address key uncertainties; assess the performance of the evidence-based model for ranking the selected product categories and identify next steps for model refinement; and where applicable and feasible, consider the potential effects on population health if risk-reduction strategies curtail the beneficial use of products.
- NLM CatalogRelated NLM Catalog Entries
- Review A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration[ 2011]Review A Risk-Characterization Framework for Decision-Making at the Food and Drug AdministrationNational Research Council (US) and Institute of Medicine (US) Committee on Ranking FDA Product Categories Based on Health Consequences, Phase II. 2011
- Biomedical applications of tissue engineering technology: regulatory issues.[Tissue Eng. 1995]Biomedical applications of tissue engineering technology: regulatory issues.Hellman KB. Tissue Eng. 1995 Summer; 1(2):203-10.
- Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine.[Workplace Health Saf. 2015]Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine.Phillips JA, Holland MG, Baldwin DD, Gifford-Meuleveld L, Mueller KL, Perkison B, Upfal M, Dreger M. Workplace Health Saf. 2015 Apr; 63(4):139-64. Epub 2015 Apr 10.
- Health policy and systems research agendas in developing countries.[Health Res Policy Syst. 2004]Health policy and systems research agendas in developing countries.Gonzalez-Block MA. Health Res Policy Syst. 2004 Aug 5; 2(1):6. Epub 2004 Aug 5.
- Review Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.[Stem Cells Transl Med. 2015]Review Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.Witten CM, McFarland RD, Simek SL. Stem Cells Transl Med. 2015 Dec; 4(12):1495-9. Epub 2015 Oct 22.
- Letter Report on the Development of a Model for Ranking FDA Product Categories o...Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks
Your browsing activity is empty.
Activity recording is turned off.
See more...